Georges Gemayel - Net Worth and Insider Trading

Georges Gemayel Net Worth

The estimated net worth of Georges Gemayel is at least $1 Million dollars as of 2024-12-01. Georges Gemayel is the Director of Momenta Pharmaceuticals Inc and owns about 14,090 shares of Momenta Pharmaceuticals Inc (MNTA) stock worth over $739,443. Georges Gemayel is also the Director of Supernus Pharmaceuticals Inc and owns about 13,315 shares of Supernus Pharmaceuticals Inc (SUPN) stock worth over $486,930. Details can be seen in Georges Gemayel's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Georges Gemayel has not made any transactions after 2024-11-08 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Georges Gemayel

Georges Gemayel Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Georges Gemayel owns 5 companies in total, including Momenta Pharmaceuticals Inc (MNTA) , Supernus Pharmaceuticals Inc (SUPN) , and Dimension Therapeutics Inc (DMTX) among others .

Click here to see the complete history of Georges Gemayel’s form 4 insider trades.

Insider Ownership Summary of Georges Gemayel

Ticker	Comapny	Transaction Date	Type of Owner
MNTA	Momenta Pharmaceuticals Inc	2020-10-01	director
SUPN	Supernus Pharmaceuticals Inc	2024-11-08	director
DMTX	Dimension Therapeutics Inc	2017-11-07	director
		2016-10-24	director
		2021-11-15	director & See Remarks

Georges Gemayel Latest Holdings Summary

Georges Gemayel currently owns a total of 2 stocks. Among these stocks, Georges Gemayel owns 14,090 shares of Momenta Pharmaceuticals Inc (MNTA) as of August 5, 2020, with a value of $739,443 and a weighting of 60.3%. Georges Gemayel also owns 13,315 shares of Supernus Pharmaceuticals Inc (SUPN) as of November 8, 2024, with a value of $486,930 and a weighting of 39.7%.

Latest Holdings of Georges Gemayel

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
MNTA	Momenta Pharmaceuticals Inc	2020-08-05	14,090	52.48	739,443
SUPN	Supernus Pharmaceuticals Inc	2024-11-08	13,315	36.57	486,930

Holding Weightings of Georges Gemayel

Georges Gemayel Form 4 Trading Tracker

According to the SEC Form 4 filings, Georges Gemayel has made a total of 2 transactions in Momenta Pharmaceuticals Inc (MNTA) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Momenta Pharmaceuticals Inc is the sale of 10,000 shares on August 5, 2020, which brought Georges Gemayel around $330,000.

According to the SEC Form 4 filings, Georges Gemayel has made a total of 3 transactions in Supernus Pharmaceuticals Inc (SUPN) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Supernus Pharmaceuticals Inc is the sale of 10,787 shares on November 8, 2024, which brought Georges Gemayel around $391,568.

Insider Trading History of Georges Gemayel

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Georges Gemayel Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Georges Gemayel Ownership Network

Ownership Network List of Georges Gemayel

No Data

Ownership Network Relation of Georges Gemayel

Georges Gemayel Owned Company Details

What does Momenta Pharmaceuticals Inc do?

Who are the key executives at Momenta Pharmaceuticals Inc?

Georges Gemayel is the director of Momenta Pharmaceuticals Inc. Other key executives at Momenta Pharmaceuticals Inc include Chief Legal Officer Alejandra Carvajal , Chief Scientific Officer Anthony M. Manning , and SVP & Chief Medical Officer Santiago Arroyo .

Momenta Pharmaceuticals Inc (MNTA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Momenta Pharmaceuticals Inc (MNTA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Momenta Pharmaceuticals Inc (MNTA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Momenta Pharmaceuticals Inc (MNTA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Momenta Pharmaceuticals Inc Insider Transactions

No Available Data

What does Supernus Pharmaceuticals Inc do?

Who are the key executives at Supernus Pharmaceuticals Inc?

Georges Gemayel is the director of Supernus Pharmaceuticals Inc. Other key executives at Supernus Pharmaceuticals Inc include director & President & CEO Jack A. Khattar , Sr VP & Quality & GMP Oper. & IT Frank Mottola , and Sr. VP of IP & CSO Padmanabh P. Bhatt .

Supernus Pharmaceuticals Inc (SUPN) Insider Trades Summary

Over the past 18 months, Georges Gemayel made 3 insider transaction in Supernus Pharmaceuticals Inc (SUPN) with a net sale of 38,886. Other recent insider transactions involving Supernus Pharmaceuticals Inc (SUPN) include a net sale of 98,505 shares made by Padmanabh P. Bhatt , a net sale of 21,235 shares made by Tami Tillotson Martin , and a net sale of 250,000 shares made by Jack A. Khattar .

In summary, during the past 3 months, insiders sold 323,308 shares of Supernus Pharmaceuticals Inc (SUPN) in total and bought 0 shares, with a net sale of 323,308 shares. During the past 18 months, 455,751 shares of Supernus Pharmaceuticals Inc (SUPN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 455,751 shares.

Supernus Pharmaceuticals Inc (SUPN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Supernus Pharmaceuticals Inc Insider Transactions

No Available Data

What does Dimension Therapeutics Inc do?

Who are the key executives at Dimension Therapeutics Inc?

Georges Gemayel is the director of Dimension Therapeutics Inc. Other key executives at Dimension Therapeutics Inc include other: See Remark 1 Fmr Llc , director & President and CEO Annalisa Jenkins , and Chief Operating Officer Mary Thistle .

Dimension Therapeutics Inc (DMTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dimension Therapeutics Inc (DMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dimension Therapeutics Inc (DMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dimension Therapeutics Inc (DMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dimension Therapeutics Inc Insider Transactions

No Available Data

What does Raptor Pharmaceutical Corp do?

Who are the key executives at Raptor Pharmaceutical Corp?

Georges Gemayel is the director of Raptor Pharmaceutical Corp. Other key executives at Raptor Pharmaceutical Corp include Chief Medical Officer Krishna R Polu , Chief Financial Officer Michael P Smith , and Chief Commercial Officer David Happel .

Raptor Pharmaceutical Corp (RPTP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Raptor Pharmaceutical Corp (RPTP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Raptor Pharmaceutical Corp (RPTP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Raptor Pharmaceutical Corp (RPTP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Raptor Pharmaceutical Corp Insider Transactions

No Available Data

What does Disc Medicine Inc do?

Who are the key executives at Disc Medicine Inc?

Georges Gemayel is the director & See Remarks of Disc Medicine Inc. Other key executives at Disc Medicine Inc include Chief Medical Officer William Jacob Savage , director & 10 percent owner Orbimed Advisors Llc , and director & 10 percent owner Mona Ashiya .

Disc Medicine Inc (IRON) Insider Trades Summary

Over the past 18 months, Georges Gemayel made no insider transaction in Disc Medicine Inc (IRON). Other recent insider transactions involving Disc Medicine Inc (IRON) include a net sale of 48,126 shares made by William Richard White , a net sale of 46,666 shares made by William Jacob Savage , and a net sale of 75,429 shares made by Kevin Bitterman .

In summary, during the past 3 months, insiders sold 35,836 shares of Disc Medicine Inc (IRON) in total and bought 0 shares, with a net sale of 35,836 shares. During the past 18 months, 3,938,062 shares of Disc Medicine Inc (IRON) were sold and 388,891 shares were bought by its insiders, resulting in a net sale of 3,549,171 shares.

Disc Medicine Inc (IRON)'s detailed insider trading history can be found in Insider Trading Tracker table.

Disc Medicine Inc Insider Transactions

No Available Data

Georges Gemayel Mailing Address

Above is the net worth, insider trading, and ownership report for Georges Gemayel. You might contact Georges Gemayel via mailing address: 550 Hills Drive, Bedminster Nj 07921.

Discussions on Georges Gemayel

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.